Association between exposure to proton pump inhibitors and delirium: a descriptive and disproportionality analysis of VigiBase
Authors:
Open Access
Abstract
Objectives Proton pump inhibitor (PPI) exposure can lead to hyponatraemia, which is a common cause of delirium. An association between PPI exposure and delirium without hyponatraemia has been suggested in the literature. We aimed to describe the association between reports of delirium and PPI exposure and to assess the association between PPI and delirium with and without hyponatraemia. Design A descriptive and disproportionality analysis of claims data. Setting World pharmacovigilance database VigiBase between 1 January 1991 and 9 February 2022. Primary and secondary outcome measures In the first part, we described reports of delirium for which involvement of a PPI or interactions of PPIs with other drugs were suspected. In the second part, delirium cases and non-cases were used to assess the disproportionality signal using the reporting OR (ROR) for the associations of PPI exposure with delirium or delirium/hyponatraemia co-events. Results We identified 2395 reports of delirium in which involvement of PPI exposure was suspected. Omeprazole, esomeprazole and pantoprazole were the most frequently reported PPIs. Hyponatraemia was present in 11% of the reports. The disproportionality analysis included 1 264 798 reports of adverse drug reactions in patients using PPIs, including 19 081 reports of delirium. We did not find a disproportionality signal for the association between PPI use and delirium (ROR 0.89, 95% CI 0.87 to 0.91). We detected an association of PPI use with delirium/hyponatraemia co-events (ROR 1.53, 95% CI 1.41 to 1.65). Conclusions Most reports of delirium in which the involvement of PPIs was suspected did not include concomitant hyponatraemia. However, no significant signal of disproportionate reporting of delirium was observed for PPIs compared with other drugs, except in cases of delirium associated with hyponatraemia. Hyponatraemia may be the main mechanism linking PPI exposure with delirium, and this possibility should be further explored in prospective studies. Trial registration number NCT05815550.Keywords
This publication has 27 references indexed in Scilit:
- Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme—A plausible missing link for their association with incidence of dementiaAlzheimer's & Dementia, 2020
- Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population–based case–control studyEuropean Journal of Internal Medicine, 2019
- Les études cas–non cas : principe, méthodes, biais et interprétationsTherapies, 2018
- Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An UpdateDrug Safety, 2014
- vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality IssuesDrug Safety, 2013
- Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12DeficiencyJAMA, 2013
- Neuropathogenesis of Delirium: Review of Current Etiologic Theories and Common PathwaysThe American Journal of Geriatric Psychiatry, 2013
- Proton Pump Inhibitors and Risk of 1-Year Mortality and Rehospitalization in Older Patients Discharged From Acute Care HospitalsJAMA Internal Medicine, 2013
- Delirium Predicts 12-Month MortalityArchives of internal medicine (1960), 2002
- Omeprazole-induced deliriumJournal of Neurology, 2000